Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Teleflex (TFX), HealthTrust Rebond On Respiratory Products

By Zacks Investment ResearchStock MarketsDec 17, 2017 09:12PM ET
www.investing.com/analysis/teleflex-tfx-healthtrust-rebond-on-respiratory-products-200274011
Teleflex (TFX), HealthTrust Rebond On Respiratory Products
By Zacks Investment Research   |  Dec 17, 2017 09:12PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
AMZN
+0.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
TFX
-0.05%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

The respiratory division of Teleflex Incorporated (NYSE:TFX) has recently entered into a new group purchasing agreement with HealthTrust Purchasing Group (“HPG”) for respiratory heaters and accessories. The agreement by the name The Respiratory Heaters & Accessories (HPG-6071) became effective on Dec 1, 2017.

The agreement covers Teleflex’s full line of Active Humidification, Non Invasive Ventilation (NIV) and High Flow Nasal Cannula Therapy (“HFNCT”) products. More than 400 member hospitals of HealthTrust can now access Teleflex’s wide range of humidification products including the Hudson RCI Neptune Heated Humidifier with ConchaSmart Technology and ISO-GardHeated Wire Circuit Technology besides the recent introduction of Comfort FloPlus High Flow Nasal Cannula.

The contract also complements Teleflex’s existing General Respiratory Agreement (HPG-184) with HealthTrust. Both these contracts — exclusive for Teleflex — provide HPG members with an opportunity to consolidate their respiratory purchases with a single supplier.

Notably, HFNCT has been growing at 20% rate year over year. This therapy has been shown to improve patient outcomes and reduce 90-day mortality rates compared with noninvasive ventilation and Standard Oxygen Therapy. Based on this data, we expect Teleflex’s deal with HealthTrust to be strategically accretive to the former and might as well boost its top line significantly in the coming period.

Taking cues from above, Teleflex has been putting in a lot of efforts on strategic expansion and top-line growth. In September, the company had made a substantial investment in the growing field of Urology. It has made a $1.1 billion acquisition of NeoTract, a privately-held developer of minimally invasive and clinically effective devices.

Apart from strengthening Teleflex’s presence in the Urology market, the company expects this buyout to accelerate the company's near-term sales growth trajectory and provide it with significant sales channel opportunity. Additionally, this should enhance Teleflex's organic growth profile in the long term.

Over the past three months, Teleflex has been trading above the broader industry. The stock has gained 5.2% compared with the broader industry’s 1.1% gain during the period.

Zacks Rank & Key Picks

Teleflex carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are PetMed Express, Inc. (PETS), Align Technology, Inc. (ALGN) and Luminex Corporation (LMNX). Notably, PetMed, Align Technology and Luminexsport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 97.5% over a year.

Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 133% in a year.

Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 5.2% over the past three months.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



PetMed Express, Inc. (PETS): Free Stock Analysis Report

Teleflex Incorporated (TFX): Free Stock Analysis Report

Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report

Align Technology, Inc. (ALGN): Free Stock Analysis Report

Original post

Zacks Investment Research

Teleflex (TFX), HealthTrust Rebond On Respiratory Products
 

Related Articles

Teleflex (TFX), HealthTrust Rebond On Respiratory Products

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email